News | September 10, 2024
Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Subscribe To Our Newsletter & Stay Updated
